# DESCRIPTION

## FIELD OF THE INVENTION

- relate to glycoconjugate vaccine

## BACKGROUND TO THE INVENTION

- introduce vaccines
- describe subunit vaccines
- limitations of subunit vaccines
- motivate glycoconjugates
- describe licensed glycoconjugate vaccines
- limitations of current glycoconjugate production
- introduce protein glycosylation locus
- describe PgIB oligosaccharyltransferase
- motivate tularemia vaccine development

## STATEMENT OF INVENTION

- provide vaccine composition
- define carrier polypeptide
- describe antigenic polysaccharide
- specify O-antigen structure
- provide immunogenic composition
- describe adjuvant
- list adjuvant examples
- define carrier
- describe T-cell epitopes
- describe B-cell epitopes
- provide multivalent antigenic composition
- describe additional anti-bacterial agent
- provide vaccine composition for Francisella infection
- specify Francisella tularensis
- provide method to treat Francisella infection
- describe antigenic polypeptide
- provide modified bacterial cell
- describe nucleic acid molecule
- specify oligosaccharyltransferase
- describe hybridization conditions
- provide variant oligosaccharyltransferase
- describe conservative amino acid substitutions
- specify identity percentage
- integrate oligosaccharyltransferase into bacterial genome
- integrate carrier polypeptide into bacterial genome
- provide bacterial cell culture
- describe process for glycoconjugate production
- provide cell culture vessel
- specify fermentor
- describe bacterial culture conditions
- specify carbon source
- specify nitrogen source
- specify inorganic salts
- specify vitamins and trace elements
- describe chelating agents
- specify growth promoters
- describe media sterilization
- specify culture temperature
- specify pH range
- describe foaming control

## Materials and Methods

### Bacterial Strains and Plasmids

- describe bacterial strains and plasmids

### Cloning, Sequencing and Expression of the F. Tularensis O Antigen Coding Region

- clone and sequence F. tularensis O antigen coding region

### Production and Purification of Glycoconjugate Vaccine

- grow E. coli CLM24
- induce expression of exoA and CjpgIB
- harvest cells and lyse
- purify His-tagged ExoA
- estimate protein yields
- perform large-scale protein purification
- generate'sham' C. jejuni heptasaccharide ExoA glycoconjugate
- describe purification process

### Immunoblot Analysis

- verify transfer and presence of F. tularensis O antigen

### Cytokine Response Analysis

- assess cytokine response

### BALB/c Mouse Challenge Studies

- describe immunisation and challenge protocol
- monitor survival and bacterial load

### Statistical Analysis

- perform statistical analysis

## Production and Purification of Glycoconjugate Vaccine

- grow E. coli CLM24
- induce expression of exoA and CjpgIB
- harvest cells and lyse
- purify His-tagged ExoA

### Protein Expression

- grow E. coli CLM24
- induce expression of acceptor protein and pgIB
- purify His-tagged ExoA

## EXAMPLE 1

### Expression of the F. tularensis SchuS4 O-Antigen in E. coli DH5α Cells

- express F. tularensis O antigen in E. coli DH5α cells

## EXAMPLE 2

### CjPgIB can Transfer F. tularensis O-Antigen to the Acceptor Protein Exotoxin A

- express CjPgIB and ExoA in E. coli CLM24 cells
- purify His-tagged ExoA
- demonstrate O-antigen transfer to ExoA

## EXAMPLE 3

### Vaccination with the Glycoconjugate Provides Significant Protection Against F. tularensis Subsp. Holarctica Infection in Mice

- describe vaccination protocol
- monitor antibody levels and survival
- compare protection between vaccine groups

## EXAMPLE 4

### Mice Vaccinated with Test Glycoconjugate and Challenged with F. tularensis Subsp. Holarctica have Lower Bacterial Loads and Pro-Inflammatory Cytokines 3 Days Post Challenge

- evaluate bacterial loads and inflammatory responses

### EXAMPLE 5

- assess IgG immune response

